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1. Introduction 
Several methods can be used to treat patients with epilepsy: antiepileptic drugs(AED), 
surgery and neuromodulation. AED is the most common method and also the first choice in 
the treatment of epilepsy. However, some patients are drug-resistant, or encounter severe 
adverse effects. In this case, surgery is an alternative to drug therapy for part of these 
patients. But surgery has several drawbacks: one is its invasive, the other is its high cost, and 
the third is its requirement for highly equipped medical devices to delineate the 
epileptiogenic zones. These factors limit its wide use in the clinical field.  
Epileptic conditions are characterized by an altered balance between excitatory and 
inhibitory influences at the cortical level(Tassinari et al.,2003). Antiepileptic drugs work by 
counteracting such imbalance with different mechanisms(Kwan et al.,2001). It is well known 
that the excitability of cortical networks can be modulated in humans by trains of regularly 
repeated magnetic stimuli(Wassermann&Lisanby,2001). Therefore, Repetitive transcranial 
magnetic stimulation (rTMS), a noninvasive and easily applied technology, could even have 
therapeutic effect in epileptic patients. Although some conflicting results have been 
reported, growing evidence shows that low-frequency (<1Hz) rTMS (slow rTMS) can 
significantly reduce seizure frequency and interictal epileptiform discharges. In this chapter, 
we aim at providing the reader with the most recent information on the application of TMS 
in epileptic conditions. 
This chapter is composed of 6 sections. First, the different ways and parameters that TMS 
can be used to investigate cortical pathophysiology are introduced. According to the 
patterns of stimulation, TMS can be divided into at least 3 categories: single-pulse TMS 
(sTMS), paired-pulse TMS (pTMS) and repetitive TMS (rTMS). Each TMS may reflect 
different brain cortical functions or have different physiologic effects. The parameters used 
as TMS study include motor evoked potential (MEP), motor threshold (MT), cortical silent 
period (CSP), intracortical inhibition (ICI) and intracortical facilitation (ICF). These 
parameters can reflect the functional state in motor cortex and motor pathway in different 
ways. 
The second section will discuss the possible antiepileptic mechanisms of rTMS in four 
aspects: electrophysiology, neurotransmitters, ion channel structure and function, as well as 
neuronal insults. 
The third section will refer to two issues: the effects of different AEDs on TMS parameters; 
the relationship between the changes of TMS parameters and corresponding AED serum 
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concentrations. The available data suggest that TMS may be a promising tool both in 
clarifying still-debated mechanisms of action of some AEDs and in optimizing the treatment 
of patients affected by epileptic seizures. 
We will review the therapeutic effect of rTMS on patients with epilepsy in the fourth section. 
Although conflicting results have been reported, growing evidence supports slow frequency 
rTMS is effective in reducing seizure frequency and /or decreasing the EEG epileptiform 
abnormalities. Some problems will be also referred to in this section. 
The safety issue of rTMS is another topic for this chapter. Currently available data showed that 
TMS is a safe technique, both in normal subjects and neurologically impaired patients. No 
long-lasting effects on cognitive, motor or sensory functions have been reported. As far as 
seizures are concerned, only 6 seizures have been elicited by rTMS in 6 non-epileptic 
individuals by the end of 1996. Although high-frequency rTMS may induce accidental seizures 
in normal subjects and epileptics, slow frequency rTMS has not been shown to induce seizures 
in patients with epilepsy. The safety issue of TMS will address in a separate paragraph. 
The final section will discuss the prospects of rTMS. As a noninvasive, easily applied and 
safe technology, rTMS may be an effective adjunctive treatment for patients with refractory 
epilepsy, and may provide a valuable insight into pathophysiological mechanisms 
underlying epileptic processes and AED-induced changes of the excitability of cortical 
networks. In addition, rTMS changes induced by different AEDs could be used as a 
neurophysiological index to optimize the treatment in a given patient. More work is needed 
to do before wide use of rTMS in the epileptic field.  
2. TMS techniques and measures of motor excitability 
TMS has mainly three categories: single-pulse TMS (sTMS), paired-pulse TMS (pTMS) and 
repetitive TMS (rTMS). Single-pulse TMS refers to stimulation with a conventional 
stimulator, which delivers pulses no faster than 1 Hz. It can be used to obtain motor 
threshold (MT) and cortical silent period (CSP). Paired-pulse TMS techniques involve a 
conditioning pulse followed by a test stimulus, which are delivered to the same scalp 
position through a single coil. It has been used to study intracortical inhibition and 
facilitation. Repetitive TMS indicates trains of regularly repeated magnetic pulses delivered 
to a single scalp site(Wassermann,1998). It can also stimulate neurons in unresponsive 
period, thus preferentially activating tangentially-oriented connecting neurons, which 
produce excitatory postsynaptic potentials and disrupt the balance between cortical 
excitability and inhibition.  
The parameters used to study experimentally and clinically mainly include motor evoked 
potential (MEP), motor threshold (MT), cortical silent period (CSP), intracortical inhibition 
(ICI), and intracortical facilitation (ICF). MEP reflects the excitability of the whole 
corticospinal system. MEP size increases with contraction of the target muscle, and increases 
with stimulus intensity in a sigmoid manner. The part of the MEP intensity curve close to 
MT is determined by the excitability of low-threshold corticospinal neurons, and the high-
intensity part of the MEP intensity curve reflects the excitability of high-threshold neurons 
(Devanne et al.,2002). MEP size may be modulated by inputs to motor cortex from the 
periphery or other parts of the brain. MEP is a reliable tool to monitor focal cortical 
excitability.  
MT is the minimum stimulus intensity needed to elicit a small motor response in the target 
muscle, in at least half of 10 consecutive trials. MT can be determined at rest (RMT) or 
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during slight isometric muscle activation (AMT). RMT is determined by the excitability of 
corticocortical axons and the excitability of synaptic contacts between these axons and 
corticospinal neurons and between corticospinal neurons and their target motorneurons in 
the spinal cord. Whereas, AMT is mainly determined by the excitability of corticocortical 
axons and therefore mainly reflects membrane-related excitability and correlates with ion 
channels(Hallett ,2007). 
CSP refers to a period of silence in the electromyographic pattern of a voluntarily contracted 
target muscle. Its size reflects the length of intracortical inhibition. The early part of the CSP 
reflects the inhibitory effect at spinal level, and the late part reflects inhibition at the level of 
the motor cortex. It is conceived that the late part of the CSP is determined by long-lasting 
cortical inhibition mediated through the γ-aminobutyric acid type B receptor(Hallett,2007; 
Ziemann et al.,2006).  
Intracortical inhibition (ICI) and intracortical facilitation (ICF) are two parameters provided 
by pTMS, which reflect neuronal inhibition and excitability, respectively. It is thought that 
paired-pulse measures reflect mainly synaptic excitability of various inhibitory and 
excitatory neuronal circuits at the level of the motor cortex. This synaptic excitability is 
controlled mainly by neurotransmission through the GABA and N-methyl-D-aspartate 
(NMDA) receptors. Short-interval intracortical inhibition (SICI) and long-interval 
intracortical inhibition (LICI) underlie separate mechanisms and may reflect inhibition 
mediated through the GABAA and GABAB receptors, respectively(Ziemann et al.,2006; 
Sanger  et al 2001).  
3. Possible antiepileptic mechanisms of rTMS 
The pathogenic mechanism of epilepsy is very complicated. It may involve several aspects, 
including the imbalance of cortically excitatory and inhibitory activities, disturbance of 
neurotransmitter, abnormality of the structure and/or function of ion channels, decrease of 
endogenous neuropeptides, and metabolic disorder in the brain. Whether rTMS affects 
epileptic seizure through one or more abovementioned factors is almost unknown. Some 
pilot researches in this aspect are summarized as follows. 
3.1 Electrophysiologic mechanism 
Some clinical studies found that RMT and intracortical inhibition in untreated epileptic 
patients decreased remarkably, and the more the RMT decreased, the more frequently the 
seizure attacked(Kotova &Vorob’eva,2007). Inghilleri et al reported that CSP in the 
epileptogenic hemisphere was much shorter than in the contralateral hemisphere(Inghilleri  
et al.,1998). Cincotta and coworkers found CSP got much longer after receiving 30 minutes, 
0.3 Hz rTMS(Cincotta et al.,2003). These studies suggested, for one thing, that imbalance 
between excitatory and inhibitory neurons existed unquestionably, for another, that rTMS 
may strengthen the inhibitory effect and therefore regain a new balance, thus leading the 
seizure decrease or remission. In our recent study, we found that the rats injected 
intraperitoneally  with epileptogenic dose of pilocarpine immediately followed by 40-
minute  rTMS treatment (0.5 Hz, 95% RMT ) had much milder seizure and lower rate of SE 
development in 90-minute follow-up period, compared with rats without rTMS treatment 
(not published). This result makes us reasonably infer that the quick antiepileptic effect of 
rTMS more likely resulted from its direct modulation on the activity of excitatory and 
inhibitory neurons in the cortex than from its indirect effect by inducing the enhancement of 
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endogenous inhibition. Therefore, Modulating the excitability and inhibition in the cortical 
neurons may be one of the antiepileptic mechanisms of rTMS. 
3.2 Neurotransmitter mechanisms 
Neurotransmitters in the brain functionally include excitatory neurotransmitters and 
inhibitory neurotransmitters, which represent by glutamate andγ-aminobutyric acid, 
respectively. In normal state, the excitatory neurotransmitters and the inhibitory 
neurotransmitters maintain a balance. Once the activity of excitatory neurotransmitters 
becomes hyperactive, or the activity of inhibitory neurotransmitters remarkably decreases, a 
seizure may occur. N-methyl-D-aspartate (NMDA) receptor-1 is one of the most important 
glutamate receptors and also the main mediator of calcium ion channel and epileptogenic 
factor. GAD65 is the key enzyme in the process of GABA synthesis and it has the quality of 
high specificity and stability. Therefore, NMDAR1 and GAD65 usually act as two marks to 
evaluate the levels of glutamate and GABA in the brain, respectively.  
Zhang et al in the rat pilocarpine seizure model found that the rats pretreated with two-
week rTMS (administered at 0.5 Hz, 95%MT) had increased expression of GAD65 and 
decreased expression of NMDAR1 in the hippocampal CA1, which investigated at 90 
minutes after injecting pilocarpine(Zhang et al.,2008). Michael et al in the study of healthy 
volunteers adopted proton magnetic resonance spectroscopy (MRS) to investigate the effects 
of high frequency rTMS on brain metabolism. They found that the content of glutamate had 
a pronounced change not only around the stimulating zone but also the remote areas 
(ipsilateral and contralateral to the stimulus site) (Michael et al.,2003). Zangen et al in the 
experimental study also found that the glutamate in the stimulated left prefrontal cortex 
increased significantly after high frequency rTMS(Zangen&Hyodo,2002). These results 
suggested that low-frequency and high-frequency rTMS may have different effects on 
excitatory and inhibitory neurotransmitters or their receptors. The antiepileptic effect of 
low-frequency rTMS might be related to the upregulation of GAD65 expression and 
downregulation of NMDAR1 in the hippocampus.  
Clinical study on patients with epilepsy revealed a dynamic change for ICI and 
ICF(Turazzini et al.,2004). The CSP had no longer linear relation with the stimulus intensity 
when the patients with focal epilepsy were administered at a certain stimulus 
intensity(Cicineli et al.,2000). Some researchers reported that the changes of GABA receptors 
are proportional to the changes of ICI, whereas the changes of glutamate receptors are 
proportional to the changes of ICF(Sanger et al.,2001; Hamer et al.,2005; Issac,2001). In 
addition, some studies demonstrated that the late part of CSP was determined by LICI, 
which was mediated through GABAB receptors. 
3.3 Ion channel structure and function mechanisms 
It is clear that seizures are linked to membrane potentials, ionic fluxes, and action potential 
generation. In neurons, action potential generation results primarily from changes in the 
membrane permeability to four ions: sodium, chloride, calcium, and potassium. These ions 
enter and exit neurons by way of voltage-dependent channels. Once the ion channel 
functions abnormally, the ionic concentrations intracellularly and extracellularly will 
probably change and result in ictal discharges or seizures.  
Genetic study has shown that the mutation of the gene coping KCNQ2 and KCNQ3 leads to 
benign neonatal familial convulsions. But whether or not rTMS is able to affect the gene of 
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ion channels is unknown. Theodore found that rTMS was able to change the flow velocity 
and distribution of sodium and calcium, and therefore affect membrane permeability 
(Theodore ,2003). Our most recent study, pretreating rats for two weeks with 0.5 Hz rTMS 
before making pilocarping-induced model, showed that rTMS can transiently downregulate 
the expression of sodium channel subunit SCN1A, but upregulate the expression of 
potassium channel subunit Kcal 1.1 in the hippocampus, and the latter effect maintained at 
least six weeks (not published). These results suggest that by changing the expression of ion 
channel genes may be another antiepileptic mechanism of rTMS. 
3.4 Protective mechanism 
It is well known that the over expression of Bcl-2 can inhibit neuron apoptosis resulted from 
multiple factors, such as overload of calcium, oxygen free radicals, glutamate and deficiency 
of neural growth factors(Zhong et al.,1993). This may be one of the self rescue mechanisms. 
Ke et al found that one-week daily rTMS before making rat pilocarpine seizure model can 
lead to Bcl-2 upregulation in the hippocampus CA1(Ke et al.,2010). Song et al in a similar 
study also found that rTMS can inhibit neuronal apoptosis, lessen necrosis resulted from 
apoptosis in the temporal tissue(Song&Tian,2004). MRS study showed that the hippocampal 
content of choline-containing compounds (CHO) in the rTMS treated chronic temporal lobe 
epilepsy (TLE) rats was much lower than that in the rTMS untreated chronic TLE rats. This 
implied that rTMS delayed or alleviated gliosis in the rTMS treated TLE rats(Song 
&Tian,2005). Post et al. in their study found that rTMS resulted in a significant increase of 
secreted amyloid precursor protein (SAPP) in the hippocampal neurons, which is a kind of 
spanning membrane glucoprotein, similar to cell surface receptor in structure(Postet 
al.,1999). SAPP has multiple effects, including protecting neurons, promoting cell survival, 
and stimulating neuronal axon growing. The above-mentioned study suggested that rTMS 
may have the ability to protect against the insult from TLE. This effect may be its another 
mechanism in counteracting epilepsy, especially chronic epilepsy. 
3.5 Other mechanisms 
3.5.1 Metabolism 
Some studies showed that both high-frequency rTMS and low-frequency rTMS can change 
the brain metabolism, not only in the stimulating areas, but also in the remote 
zones(Michael et al.,2003;Song &Tian,2005; McCann et al.,1998). In a clinical trial, Speer 
adopted high-frequency rTMS (20 Hz) and low-frequency rTMS (1 Hz) to treat patients with 
depression, and used positive emission tomography(PET) to measure the brain metabolism. 
They found that high-frequency rTMS had a better outcome in patients with 
hypermetabolisms, but low-frequency rTMS had a better outcome in patients with 
hypometabolisms(Speer et al.,2009). This result suggested that high-frequency rTMS and 
low-frequency rTMS may affect the brain metabolisms in opposite way: low-frequency 
rTMS reduces metabolism, high-frequency rTMS enhances metabolism. It is therefore 
reasonably deduced that the antiepileptic effect of low-frquency rTMS may be related to its 
ability to reduce the brain metabolism. 
3.5.2 Regional cerebral blood flow (rCBF) 
Both high-frequency rTMS and low-frequency rTMS can affect the change of regional 
cerebral blood flow in the stimulated areas. Graff-Guerrero et al described two patients with 
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epilepsia partialis continua(Graff-Guerrero et al.,2004). They investigated these two patients 
by single photon emission computed tomography (SPECT) before and after rTMS treatment. 
They found that both have hyperperfusion in the epileptogenic zones before rTMS. But this 
phenomenon abolished after rTMS treatment. Therefore, modulation of rCBF around the 
epileptogenic zone may contribute to the control of seizures. 
3.5.3 Endogenous antiepileptic mechanism 
Anschel et al did an interesting experiment. In this study, they administered a patient with 
depression with rTMS for 8 consecutive days, then they injected the cerebrospinal flow into 
the lateral ventricle of rats. They surprisingly found that the flurothyl-kindling effect was 
significant mitigated(Anschel et al,2003). This result suggested that the CSF of the rTMS 
treated patient must contain some endogenous antiepileptic substance. Therefore, it 
reasonably infers that rTMS may have the ability to stimulate the release of some 
endogenous antiepileptic substances. 
4. Effects of AEDs on TMS parameters and their clinical values  
4.1 TMS parameters versus AEDs and their possible mechanisms 
Extant data show that the effects of different antiepileptic drugs on TMS parameters are 
variable. It has been found that the MT is increased after acute administration of the voltage-
dependent sodium channel blockers carbamazepine (CBZ), lamotrigine (LTG), and 
phenytoin (PHT)( Boroojerdi et al.,2001), and the maximum MT was observed at the plasma 
peak time in normal subjects(Ziemann et al.,1996). These findings were also reported in 
epileptic patients. However, many patients were under chronic AED treatment at the time of 
TMS testing. This suggests that the increased MT may result from the threshold increasing 
effect of AEDs in epileptic patients. This view was directly supported by the demonstration 
that untreated groups of patients with idiopathic generalized epilepsy(IGE)( Reutens et 
al.,1993) or benign epilepsy with centrotemporal spikes(Nezu et al.,1997) had reduced or 
normal RMT values compared with healthy controls. However, RMT in the patient groups 
increased significantly above normal level when remeasured after the commencement of 
treatment with valproic acid(Reutens et al.,1993; Nezu et al.,1997). In a study on temporal 
lobe epilepsy patients, RMT significantly increased with the number of AEDs taken by the 
patients(Hufnagel et al.,1990). In one subgroup of this study, RMT dropped significantly 
after tapering AED treatment(Hufnagel et al.,1990). On the contrary, some studies found 
RMT is increased in untreated IGE patients(Gianelli et al.,1994). This elevation of MT may 
reflect cortical dysfunction after the seizure or is likely a protective mechanism against 
spread or recurrence of seizures. For these reasons, some researchers applied TMS to 
evaluate the antiepileptic effects of PHT and CBZ monotherapy. They found a higher MT 
and a lower MEP in the PHT group than those in CBZ group, which implies PHT may have 
stronger inhibitory effect on cortical excitability compared with CBZ(Goyal et al.,2004). 
In contrast to ion channel blocker intake, a single dose of drugs enhancing γ-aminobutyric 
acid (GABA )-medicated inhibitory neurotransmission, such as baclofen, diazepam, ethanol, 
lorazepam, tiagabine, and vigabatrin, does not modify the MT in healthy subjects (Tassinari, 
2003), but may change the cortical silent period duration (CSP), intracortical facilitation 
(ICF), and intracortical inhibition (ICI) (Tassinari,2003). Reis et al found that topiramate, 
which can enhance the GABA-mediated inhibitory effect and counteract the toxic effect of 
excitatory amino acid, is able to elevate ICI but does not affect MT and CSP(Reis et al.,2002). 
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Another study showed that gabapentin had no effect on MT, but reduced the ICF, increased 
ICI and CSP(Rizzo et al.,2001). This suggests that gabapentin may enhance the GABAergic 
neurotransmission. In a study on levetiracetam, MT significantly increased, but CSP, ICI, 
and ICF unchanged(Reis et al.,2004). This implies that levetiracetam may have block effect 
on sodium channel. 
In summary, the relationship between TMS parameters and AEDs is complicated. Ziemann 
reviewed the literatures and concluded that ion channel blocker AEDs can elevate MT, but 
have no effect on CSP, ICI and ICF, whereas, enhancing GABAergic AEDs, such as 
lorazepam, diazepam, vigabatrin, and tiagabine, mainly affect CSP, SICI, ICF, SICF, but 
have no effect on MT (see table 1)(Ziemann, 2004) MEP can be used as one of the most 
sensitive indexes in investigating the effects of AEDs.  
 
drug 
Mode of 
action 
TMS variables 
MT MEP CSP SICI ICF SICF 
CBZ Na+ 1+ 0 1+ 0/0 0/1- 0 
PHT Na+ 2+ 0/0 0/0    
LTG Na+ 3+ 1- 0 0/0 0/0 0 
VPA Na+/GABA 0  0 0 0  
LZP GABA 0/0/0 2- 1+ 0/2+ 0/1- 1- 
DZP GABA 0/0 1-/0 0/1- 0/1+ 1- 1- 
TP GABA 0 1- 0    
VGB GABA 0 0/0 0/0 0 1- 1- 
TGB GABA 0 0 1+ 1- 1+  
carbamazepine: CBZ, phenytoin: PHT, lamotrigine: LTG, valproate: VPA, lorazepam: LZP, diazepam: 
DZP, thiopental: TP, vigabatrin: VGB, tiagabine: TGB; no clear change: 0, increase: 1+, clear increase: 2+, 
significant increase: 3+, decrease: 1-, clear decrease: 2-.  
Table 1. Effects of antiepileptic drugs on TMS variables 
Sohn et al(Sohn et al.,2004) summarized corresponding MEP changes after using sodium 
channel blocker LTG and GABA receptor agonist thiopental and lorazepam, and transferred 
these changes into curves. They found that both of the sodium channel blocker and GABA 
receptor agonist made the curves shift down.  
The early part of the CSP is easily affected by spinal inhibitory mechanisms, whereas the 
late part most probably reflects inhibition specifically at the level of the motor cortex 
(Hallett,2007; Ziemann et al.,2006). It is thought that this late part of the CSP is determined 
by long-lasting cortical inhibition (LICI) medicated through the GABA type B receptor. 
Interestingly, AEDs (CBZ, LZP) with different modes of action may produce similar CSP 
prolongation, whereas those with the same modes of action (LZP, DZP) may result in 
different CSP changes, which are shown in table 1(Sohn et al.,2004; Sundaresan et al., 2007). 
These inconsistent findings suggest further study is needed to clarify the relationship 
between TMS variables and AEDs.  
It is thought that LICI may reflect the long-last inhibition mediated by GABAB receptors. 
Therefore, the pronounced enhancement of LICI may be the result of the potentiated 
neurotransmission mediated through the postsynaptic GABAB receptors(Werhahn et 
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al.,1999). Short-interval intracortical inhibition (SICI) may reflect the inhibition mediated 
through GABAA receptors. Most of the GABAA receptor agonists, such as LZP, DZP may 
increase SICI. The duration of SICI correlates with that of the inhibitory postsynaptic 
potential which is mediated through GABAA receptors. Combined with inter-stimulus 
intervals, SICI can be used in ICF evaluation. This suggests that the excitatory interneurons, 
which mediate ICF, are controlled by inhibitory interneurons, and this influences are dose-
dependent(Reis et al.,2004; Ye&Zhang,2000). AEDs of sodium channel blockers exert no 
clear effect on SICI, as opposed to ICF.  
4.2 The relation between TMS variables and the plasma concentrations of AEDs 
The relation between RMT and the plasma concentration of AEDs shows a sigmoid(Della 
Paschoa et al.,2000). A study on 16 healthy subjects taking LTG showed a linear relation 
between the MT and the LTG plasma concentration (in the range of 430ng to 2500ng/ml)( 
Tergau et al.,2003). Cantello et al demonstrated that the MT and the plasma concentration, in 
a study of 15 patients with symptomatic epilepsy taking VPA, had a positive linear relation, 
whereas a sigmoid relation in 18 healthy subjects (Cantello et al., 2006). Werhahn et al 
reported that the dose of TGB had a positive linear relation with CSP and ICF. Although 
TGB can affect SICI, the relation between the dose and SICI is unclear(Werhahn et al.,1999). 
In a study of CBZ, Turazzini administered 10 patients with symptomatic epilepsy with daily 
200mg dose of CBZ, and with an increment of 200mg every other day, then maintained at 
800mg daily. They found a linear relation between RMT increases and the serum 
concentration of CBZ before a stable level after they monitored the changes of serum CBZ 
and TMS parameters at a certain interval in 2 months(Turazzini et al.,2004),. They also found 
in this study that MEP, CSP, SICI and ICF had no pronounced changes(Turazzini et 
al.,2004). Lee et al demonstrated a similar effect of CBZ and LTG on MT in the 5-week 
duration of observation in 20 volunteers, but this was mainly seen at the late stage, and can 
be explained as follow-up effect(Lee et al.,2005).  
4.3 Prospect of TMS in the study of AEDS 
TMS variables may be helpful to investigate the unknown mechanisms of some AEDs. 
Although single- and paired-pulse TMS parameters show sigh variability across subjects, 
their interside and longitudinal intraindividual variability is lower. Therefore, repeated 
recordings in the same subjects appear to be a sensitive tool to disclose minor AED-induced 
changes(Tassinari et al,2003). Furthermore, the threshold intensity varied with the changes 
of AED dose, or had a positive linear relation with serum levels of AEDs. This suggests that 
monitoring the change of TMS threshold intensity, just as monitoring the plasma drug 
concentration and electroencephalography (EEG), could be acted as a tool to guide optimum 
use of AEDs. In addition, according to the correlation of drug serum concentration and TMS 
parameters, TMS might be used as an adjunctive means to monitor brain cortical excitability 
when studying the pharmacodynamics of AEDs. This implies that TMS may be used to 
evaluate the newly developed antiepileptic drugs. 
5. The therapeutic effect of rTMS on patients with epilepsy 
5.1 Experimental animal study  
A series of animal studies have shown that low-frequency rTMS has antiepileptic effect, and 
this effect is frequency dependent. Akamatsu et al demonstrated that rTMS of 1000 pulses at 
www.intechopen.com
 
The Clinical Application of Transcranial Magnetic Stimulation in the Study of Epilepsy 
 
43 
0.5 Hz led to a prolonged latency for seizure development and a lower ratio of status 
epilepticus after an intraperitoneal injection of pentylenetetrazol in Wistar rats(Akamatsu et 
al.,2001). Godlevsy and coworkers(Godlevsky et al.,2006) experimented on male WAG/Rij 
rats with rTMS of 3 impulses at 0.5 Hz and combined recording of electrocorticograms. They 
found that such stimulation engendered a reduction of spike-wave discharge bursts 
duration, which was most pronounced in 30 minutes from the moment of cessation of 
stimulation, but bursts of spike-wave discharges restored up to pre-stimulative level in 90-
150 minutes. This result suggested that rTMS possessed an ability to produce short-time 
suppression of bursts of spike-wave discharges in WAG/Rij rats, a gene model of absence 
seizure. Rotenberg et al(Rotenberg et al.,2008) tested the anticonvulsive potential of rTMS 
with different stimulation frequency in the rat kainic acid seizure model. They divided 21 
rats into three groups in which individual seizures were treated with rTMS trains at one of 
three frequencies: 0.25, 0.5 or 0.75 Hz. The rTMS treatments were guided by simultaneous 
EEG monitoring, that is, rTMS treatment (active rTMS, sham rTMS, or untreat) was 
administered only when consecutive seizures occurred. They found that KA-induced 
seizures were abbreviated by 0.75 Hz and 0.5 Hz active EEG-guided rTMS, but neither 
active 0.25 Hz rTMS nor the control conditions affected seizure duration. This result 
indicated that rTMS has therapeutic potential, but is frequency dependent. Ke Sha et al(Ke  
et al.,2010), as well as Huang Min et al(Huang et al.,2009), also investigated the efficacy of a 
range of rTMS frequencies, but in another model: pilocarping seizure model. They divided 
rats into different groups according to the rTMS frequency delivered at the treatment, and 
pretreated each rat with corresponding frequency’s rTMS for consecutive two weeks. After 
finished the pretreatment, each rat was given an intraperitoneal injection of pilocarpine. 
They demonstrated that pretreatment with TMS at 0.3, 0.5, 0.8, and 1.0 Hz all led to a longer 
latency of seizure onset, but 0.5 Hz and 0.8 Hz rTMS treatment engendered the longest 
latency for seizure development and conspicuous anticonvulsive effects. 
5.2 Clinical study 
Tergau and coworkers(Tergan et al.,1999) first reported the treatment of rTMS on patients 
with epilepsy in 1999. In their trial, nine patients with medically refractory frontal epilepsy 
were enrolled. All patients had more than seven focal or secondarily generalized seizures 
per week in the 6 months before rTMS treatment. After rTMS, which was delivered over the 
vertex with two trains of 500 pulses at a frequency of 0.33 Hz on 5 consecutive days, weekly 
seizure frequency dropped significantly from an average of 10.3to 5.8. Seizures did not 
occur during rTMS. After 6 to 8 weeks, seizure frequency returned to baseline level. Since 
then, a lot of clinical reports were followed (see Table 2-4). Fregni et al(Fregni et al., 2006) 
randomly divided 21 patients with refractory epilepsy into active rTMS group and sham 
rTMS group. rTMs was administered with 5 trains of 1200 pulses and an intensity of 70% 
rMT at frequency of 1 Hz on 5 consecutive days. They noticed that, compared with sham 
rTMS group, the seizure frequency and the number of spikes in ictal EEG were significantly 
reduced, and their cognition was also improved after rTMS. This effect lasted at least 2 
months. Santiago-Rodriguez et al(Santiago-Rodriguez et al.,2008) evaluated the number of 
seizures and interictal epileptiform discharges (IEDs) in 12 patients with focal neocortical 
epilepsy before, during and after rTMS. rTMS was administered with 900 pulses at 0.5 Hz 
for 2 consecutive weeks at 120% rMT. They found that the mean seizure frequency 
decreased from 2.25 per week (basal period) to 0.66 per week (intervention period), a 71% 
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reduction (p=0.0036). In the 8-week follow-up period the mean seizure frequency was 1.14 
per week, which corresponds to a 50% reduction compared with basal period. Moreover, 
EEG analysis displayed IED frequency was also reduced; it decreased from 11.9 (baseline) to 
9.3 (during 2 weeks of rTMS) with a further reduction to 8.2 in the follow-up period. These 
differences on EEG however were not significant (p=0.190). Joo et al(Joo et al.,2007) 
investigated the antiepileptic effect of low-frequency rTMS in 35 patients with intractable 
epilepsy. Patients were divided into a focal stimulation group with a localized epileptic 
focus, or a non-focal stimulation group with a non-localized or multifocal epileptic focus. 
Each group was then randomly subdivided into 3000 pulses and 1500 pulses subgroups. 
rTMS was administered at 0.5 Hz for 5 consecutive days at 100% of rMT. Weekly seizure 
frequency were determined for 8 weeks before and after rTMS, and the number of interictal 
spikes before (1st day) and after rTMS (5th days) were also compared. They demonstrated 
that interictal spikes significantly decreased (-54.9%, p=0.012) and even totally disappeared 
in 6 patients after rTMS. Although mean weekly seizure frequency was non-significantly 
decreased after rTMS, longer stimulation subgroups (3000pulses,-23.0%) tended to have 
fewer seizures than shorter stimulation subgroups (1500pulses,-3.0%), without statistical 
significance. They also found TMS stimulation site and structural brain lesions did not 
influence seizure outcome. Wang et al(Wang et al.,2008)randomly divided 30 patients with 
temporal lobe epilepsy, which was determined with dipole source, into drug group and 
rTMS group, each group with 15 patients. Drug group were given antiepileptic drug only 
(AED)(camazepine, 600-800mg daily, three times a day); rTMS group were given rTMS 
treatment as well as AED (camazepine, 600-800mg daily, three times a day). rTMS was 
administered using Dantec Maglite-r25 with 500 pulses at 1 Hz for consecutive seven days 
at intensity of 90% MT. After 7 days of rTMS treatment, both groups continued to take AED. 
They found that seizure frequency had no significant difference between rTMS group and 
drug group. However, interictal spikes decreased significantly in rTMS group compared 
with drug group on the 30 th day after rTMS.  
Regrettably, the results of rTMS in the treatment of epilepsy almost exclusively came from 
interictal epileptic patients. There are very few studies based on ongoing seizures. 
Nevertheless, Rotenberg and coworkers’ study is encouraging(Rotenberg et al.,2009). In 
their study, seven patients with epilepsia partialis continua (EPC) of mixed etiologies were 
treated with rTMS over the seizure. rTMS was delivered in high-frequeny (20-100 Hz) bursts 
or as prolonged low-frequency (1 Hz) trains. The result is that rTMS led to a brief (20-30 
min) pause in seizures in three of seven patients and a lasting (no less than one days) pause 
in two of seven. Seizures were not exacerbated by rTMS in any patient. Only mild side 
effects including trainsient head and limb pain, and limb stiffening during high-frequency 
rTMS train occurred.  
Above-mentioned studies both clinically and experimentally indicate that rTMS is effective 
and safe in the treatment of epilepsy. It can not only decrease seizure frequency, but also 
reduce spikes firing, even terminate ongoing seizures. Some researchers have recommended 
rTMS to be a method to treat refractory epilepsy. Novertheless, it will be a long way before 
rTMS really puts to clinical practice. The reason is that current data about effectiveness of 
rTMS mainly resulted from small size trials, even case report, lack of convincingly large size 
and randomly controlled trials, and that the parameters (including stimulus frequency, 
intensity, number of stimuli, train duration, intertrain interval, coil type, and stimulation 
sites) used in rTMS studies or treatment are different among researchers (see table 5). This 
may be why some incongruent, even conflicting results occurred.  
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First author 
and publish 
time 
Subjects
Epilepsy 
syndorme 
Seizure 
frequency pre-
TMS 
Seizure 
frequency 
Post-TMS 
Epileptiform 
Discharges 
Post-TMS 
Menkes, 2000 1 ETLE 37/month Reduction Reduction 
Cantello, 
2002 
1 
Primary 
generalized 
NR No reduction Reduction 
Rossi, 2004 1 EPC EPC Reduction Reduction 
Graff-
Guerrero 
2004 
2 EPC EPC 
Reduction in 
one of two 
patients 
Reduction 
Misawa,2005 1 EPC EPC 
Reduction for 
two month 
NR 
Mecarelli, 
2006 
1 Focal NR Reduction No Reduction 
Brighina, 
2006 
9 
Focal=3 
Multifocal=6
NR 
Reduction only 
during protocol
NR 
ETLE=extra temporal lobe epilepsy; MTLE= mesial temporal lobe epilepsy; TLE=temporal lobe 
epilepsy; NR=not reported; EPC= Epilepsia partialis continua. 
Table 2. Impact of rTMS on epilepsy(Case report study) 
 
First author 
and publish 
time 
Subjects
Epilepsy 
syndorme 
Seizure frequency 
pre-TMS 
Seizure frequency 
post-TMS 
Epileptiform 
Discharges 
Post-TMS 
Tergau, 1999 9 
TLE=2 
ETLE=7 
10.3±6.6/w 5.8±6.4/w NR 
Daniele, 
2003 
4 
Frontal=2 
Multifocal=2 
19/month(focal),
36/month(multifo
cal) 
Reduction(in 
patients with 
single focus) 
NR 
Brasil-Neto, 
2004 
5 TLE=2 ETLE=3 1.4±0.09/d Reduction NR 
Fregni 
2005 
8 
TLE=3 
Multifocal=4 
ETLE=1 
3-6.2/w 
Reduction for 1 
month 
Reduction for 1 
month 
Kinoshita, 
2005 
7 Focal 16.5±5.2/w Reduction NR 
Santiago-
Rodriguez, 
2008 
12 Focal 2.25/w Reduction No reduction 
Rotenberg 
2009 
7 EPC EPC Reduction NR 
Wei Sun 
2011 
17 
Refractory 
partial 
14.09±16.55/w Reduction No reduction 
d=day;w=week 
Table 3. Impact of rTMS on epilepsy(Open-label study) 
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First 
author and 
publish 
time 
Subjects 
Epilepsy 
syndorme 
Seizure 
frequency pre-
TMS 
Seizure frequency 
post-TMS 
Epileptiform 
Discharges 
post-TMS 
Theodore 
2002 
12 Focal 3.4±1.2/w No reduction NR 
Tergau 
2003 
17 
MTLE/ETLE/
Multifocal/Ge
neralized 
NR 
Reduction 
(only0.33 HZ) 
NR 
Fregni 
2006 
12 Focal 13.6±10.1/28d 
Reduction 
(at least two month)
Reduction 
(at least two 
month) 
Joo 
2007 
35 
Focal/Multifo-
cal/Non-
localized 
9.9±10.1/w  
(NF group) 
7±9.6/w  
(F group) 
Trend for reduction Reduction 
Cantello, 
2007 
43 Focal 9.1±2.2/w No reduction Reduction 
Wang 2008 15 TLE 1.9±0.4/w No reduction Reduction 
Table 4. Impact of rTMS on epilepsy (Double-blinded and sham-controlled study) 
6. The safety issue of rTMS 
Although extant researches have shown that rTMS is a promising tool in treating epilepsy, 
its safety and tolerability have been the focus of concerns. rTMS does have the potential for 
short-term adverse side effects such as headache, tinnitus, insomnia, discomfort at the site of 
stimulation, but its long-term adverse side effects are unknown. Studies in normal human 
subjects have shown that rTMS had no long-term adverse effects on blood pressure, heart 
rate, balance, gait, sensory function, motor function, memory and cognition(Pascual-Leone 
et al.,1993; Hufnagel et al.,1993), and found no changes in electroencephalogram (EEG), 
electrocardiogram (ECG), serum hormone(Jahanshahi et al.,1997). Studies of the anatomical 
effects of rTMS have shown that conventional and diffusion-weighted magnetic resonance 
imaging are normal following long duration, high-intensity rTMS that exceeded safety 
guidelines, and MRI is normal following rTMS used for 2 weeks in treating depression 
(Anand S&Hotson J,2002). Moreover, no pathological changes are seen in resected temporal 
lobe tissue following approximately 2000 pulses(Gates et al.,1992). In addition, metabolic 
study showed that proton magnetic responance spectroscope (MRS) revealed no significant 
alterations of N-acetyl-aspartate, creatine and phosphocreatine, choline-containing 
compounds, myo-inositol, glucose and lactate, and post mortem histology revealed no 
changes in microglial and astrocytic activation following rTMS regimen of 1000 stimuli used 
for 5 consecutive days at 1 Hz(Liebetanz et al.,2003). 
Another safety issue of rTMS is its effect on cognition(Anand S&Hotson J,2002). Most safety 
studies have not reported adverse long-term effects in cognitive function in subjects 
receiving rTMS. One study found degradation in short term verbal memory immediately 
following rTMS, but the effect did not persist following the study and was attributed to the 
short inter-train intervals that were also cause seizures in normal subjects. Performance on 
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standard neuropsychological tests is not adversely affected by rTMS sessions; instead, 
verbal memory tends to improve and motor reaction time tends to decrease. 
 
First author and 
publish time 
Frequency
(Hz) 
Intensity Stimuli Schedule Coil form Position 
Tergau, 1999 0.33 100%rMT 500/train 5trains/d* 5d Round Vertex 
Menkes, 2000 0.5 95%rMT 20/train
5trains/ 
d*bw*3m 
Round EGF 
Cantello, 2002 5 120%MT NR Onset of spikes NR NR 
Theodore, 2002 1 120%MT 900/train 2train/d*7d 
Figure-of-
eight 
EGF 
Tergau, 2003 0.33, 1 below MT 1000/train 1train/d*5d Round Vertex 
Daniele, 2003 0.5 90%MT 100/train bw*4w, 
Figure-of-
eight 
EGF/ 
vertex 
Rossi, 2004 1 90%rMT 900 Single session 
Figure-of-
eight 
EGF 
Brasil-Neto, 2004 0.3 95%MT 20/train
5trains/d*BW*3
m 
Round Vertex 
Graff-Guerrero 
2004 
20 
50%, 
128%MT 
40/train 15days 
Figure-of-
eight 
EGF 
Fregni 2005 0.5 65%MSO 600 Single session 
Figure-of-
eight 
EGF/ 
vertex 
Kinoshita 2005 0.9 90%rMT 810/train
2trains/d*5d*/
w*2w 
Round FCz, PCz 
Fregni 2006 1 70%MSO 1200/train 1train/d* 5 d 
Figure-of-
eight 
EGF/ 
vertex 
Mecarelli 2006 0.33 100%rMT 500/train 2train/d *5 d Round Vertex 
Brighina 2006 5 100%rMT 100/train 20d 
Figure-of-
eight 
Near 
inion 
Joo, 2007 0.5 100%MT 
3000/train
/ 
1500/train
1train/d* 5 d Round 
Vertex/ 
temporal 
Cantello, 2007 0.3 
100%MT/ 
65%MSO 
500/train 2trains/d*5 d Round Vertex 
Santiago-
Rodriguez, 2008
0.5 120%rMT 900/train 1train/d*2 w 
Figure-of-
eight 
EGF 
Wang, 2008 1 90%MT 900/d 7 d 
Figure-of-
eight 
EGF 
Rotenberg, 2009 100, 20, 1 100%MT NR Difference 
Figure-of-
eight 
EGF 
bw=biweek; m=month; MSO=maximum stimulator output intensity; EGF=epileptogenic focus. 
Table 5. Brain stimulation parameters 
The third safety issue of rTMS is its effect on endocrine system(Anand&Hotson,2002). One 
study found no change in hormonal levels in humans following rTMS, but a decrease in 
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serum prolactin levels, which is opposite the effect seen after a seizure, and an increase in 
thyroid-stimulating hormone level, which accompanied an improved mood, were found 
following rTMS. 
The greatest concern with rTMS is the induction of seizures. Even in normal healthy 
subjects, prolonged, high intensity, rTMS with rate of 10-25 Hz can produce partial seizure 
with or without secondary generalization. After analyzing thousands of rTMS treated 
patients, Rosa et al(Rosa et al.,2004) think TMS is safety. They found only 6 patients had an 
occasional seizure, and the risk factors of seizures elicited by TMS included brain tumor, 
stroke, inflammation, severe trauma, increased cranial pressure, idiopathic epilepsy, 
uncontrolled epilepsy, taking some drugs which reduce the threshold of seizures such as 
tricyclic antidepressants, excessive drinking, and use of stimulant drugs. 
The guidelines released by National Healthy Institute of America in 1998 believed that rTMS 
was relative contradindication to patients with epilepsy, but safe on the condition of strictly 
controlling stimulating parameters and regular operation(Wassermann,1998). Schrader et al 
(Schrader et al.,2004) concluded from the analysis of some studies that the peak rate of 
seizure occurrence related to TMS was 2.8 percent in sTMS, 3.6 percent in pTMS, and the 
modes of onset were similar to their typical attack; no long-term adverse effects were found 
and the increased seizure frequency could not exclude the possibilities of intractable 
epilepsy, decreased use of medication, improper operation and strongly stimulating 
intensity. Studies of safety evaluation of the combinations of parameters (0.5 Hz, 50 pulses; 8 
Hz, 1000 pulses; 20 Hz, 1500 pulses; 25 Hz, 1200 pulses) showed that rTMS delivered in any 
combination of parameters was safe(Liebetanz et al.,2003; Frye et al.,2008; Post et al.,1999). 
Bae EH et al(Bae et al.,2007) performed an English-language literature search, and reviewed 
all studies published from January 1990 to February 2007 in which patients with epilepsy 
were treated with rTMS. They found that the adverse events attributed to rTMS were 
generally mild and occurred in 17.1% of subjects; headache was most common, occurring in 
9.6%; seizures occurred in 4 patients (1.4%); all but one case were the patients’ typical 
seizures with respect to duration and semiology, and were associated with low-frequency 
rTMS; a single case had atypical seizure appearing to arise from the region of stimulation 
during high-frequency rTMS; no rTMS-related episodes of status epilepticus were reported. 
They concluded that rTMS appeared to be nearly as safe in patients with epilepsy as in 
nonepileptic individuals. 
Based on the consideration of safety, current studies support to use slow-frequency rTMS 
for the purpose of treatment in epilepsy. As for selecting of parameters, which include 
stimulus frequency, intensity, intertrain interval, and stimulus site, it should depend on 
individuals and comply with some norms. Besides, the accurate localization of the stimulus 
site is also the important part of safety study(Hoffman et al.,2005).  
Wassermann (1998) provided a comprehensive report of new guidelines based on the 
deliberations of an “International Workshop on the Safety of Repetitive Transcranial 
Magnetic Stimulation, Jun 5-7, 1996.” He reiterated three requirements central to research on 
human subjects, namely, the need for informed consent, the requirements that the potential 
benefit of the research outweighs the risk as independently assessed by an investigational 
review board, and the need “for equal distributions of the burdens and the benefits of the 
research” The research should not be conducted on categories of vulnerable patients or 
subjects who are likely to bear the burden of the research without the potential for benefit. 
Wassermann suggested three types of studies appropriate for rTMS. First are studies where 
there are reasons to expect direct benefit to patients, such as the treatment of major 
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depression. Second are studies of the pathophysiology of a brain disorder that may add 
information leading to new therapeutic strategies. These studies would include the 
participation of normal subjects as controls. Third are studies in normal subjects or patients 
that are expected to produce original and important observations about brain function that 
can not be obtained by safer methods. 
7. Prospects of rTMS in the study of epilepsy 
As a noninvasive, easily applied and safe technology, rTMS may be an effective adjunctive 
treatment for patients with refractory epilepsy, and may provide a valuable insight into 
pathophysiological mechanisms underlying epileptic processes and AED-induced changes 
of the excitability of cortical networks. In addition, rTMS changes induced by different 
AEDs could be used as a neurophysiological index to optimize the treatment in a given 
patient. However, the best regimen of rTMS delivering has not been determined. Multiple 
central collaborative studies are necessary to establish optimum stimulation parameters, 
such as stimulus frequency, intensity, number of stimuli, train duration, intertrain interval, 
coil type, and stimulation sites. With study going on, it is probable that rTMS will be an 
effective therapeutic tool and be widely used in clinical practice. What’s more, it is hopeful 
that the research into mechanisms of epileptogenicity may also break through by using 
rTMS.   
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